Table 1.
Surviving sepsis campaign recommendations stratified by the presence of wards patients in the supportive evidence
| No Wards Patients in Any Supporting Study (n = wards patients/total patients in cited studies) | Only in Observational Studies (n = wards patients/total patients in cited studies) | Randomized Controlled Trials and Observational Studies (n = randomized controlled trial wards patients/observational study wards patients/total patients) |
|---|---|---|
| Early goal-directed therapy with normalized lactate (A-2) (n = 0/648) | Early goal-directed therapy with goals (A-1) (n = 5,258/35,121) | Empiric combination antibiotics duration (D-4b) (n = 1,129/1,627/11,852) |
| Cultures drawn before antibiotics (C-1) (n = 0/1,017) | Screen for severe sepsis (B-1) (n = 5,228/16,916) | |
| Imaging to identify infectious source (C-3) (n = 0/0) | Quality improvement for sepsis (B-2) (n = 30/3,039) | |
| Reassessing antibiotic regimen (D-2b) (n = 0/0) | Invasive candidiasis assays (C-2) (n = 120/599) | |
| Empiric combination antibiotics initiation (D-4a) (n = 0/551) | IV Antibiotics within the first hour (D-1) (n = 5,296/22,218) | |
| Duration of antibiotic therapy (D-5) (n = 0/0) | Activity and penetration of antibiotics (D-2) (n = 1,928/5,726) | |
| No antibiotics in the systemic inflammatory response syndrome without infection (D-7) (n = 0/0) | Biomarkers (D-3) (n = 0/3,297) | |
| Source control (E-1) (n = 0/201) | Antivirals (D-6) (n = 205/371) | |
| Pancreatic necrosis (E-2) (n = 0/124) | ||
| Intervention with least physiologic insult (E-3) (n = 0/0) | ||
| Intravascular device (E-4) (n = 0/0) | ||
| Crystalloids (G-1) (n = 0/0) | ||
| No hydroxyethyl starch (G-2) (n = 0/8,679) | ||
| Albumin (G-3) (n = 0/6,997) | ||
| Initial fluid challenge (G-4) (n = 0/0) | ||
| Hemodynamic improvement (G-5) (n = 0/0) |